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Abstract
Purpose Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast 
cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-
estrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for 
establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with 
the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC 
and facilitating clinical decision-making.
Methods This consensus document was generated using a modification of the RAND/UCLA methodology, which included 
the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an 
analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 
64 medical oncologists specializing in breast cancer.
Results A Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the 
first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local 
curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic 
decision-making.
Conclusion We have developed a consensus document with recommendations on the treatment of patients with HER2-
negative luminal MBC that will help to improve therapeutic benefits.
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 * I. Alvarez-Lopez 
 isabelmanuela.alvarezlopez@osakidetza.eus
1 Hospital Universitario Donostia–BioDonostia, Begiristain 
Doktorea Pasealekua, 109, 20014 Donostia, Gipuzkoa, Spain
2 Grupo GEICAM de Investigación en Cáncer de 
Mama/GEICAM Spanish Breast Cancer Group, San 
Sebastián de los Reyes, Madrid, Spain
3 Parc Taulí, Hospital Universitari, Sabadell, Barcelona, Spain
4 Hospital General Universitario Morales Meseguer, Murcia, 
Spain
5 Hospital Clínico San Carlos, Madrid, Spain
6 Centro de Investigación Biomédica en Red de Oncología, 
CIBERONC-ISCIII, Madrid, Spain
7 ICO Bellvitge, Hospitalet del Llobregat, Barcelona, Spain
8 Consorcio Hospitalario Provincial de Castellón, 
Castellón de la Plana, Spain
9 Unidad de Gestión Clínica Intercentros de Oncología 
Medica, Hospitales Universitarios Regional y Virgen de la 
Victoria de Málaga, 29010 Málaga, Spain
10 Instituto de Investigación Biomédica de Málaga 
(IBIMA)-CIMES-UMA, 29010 Málaga, Spain
11 Hospital Universitario y Politécnico La Fe, Valencia, Spain
1365Clinical and Translational Oncology (2020) 22:1364–1377 
1 3
Introduction
Breast cancer accounts for 30% of all cancers of the female 
gender, and is the most common malignancy in women and 
the main cause of cancer death. In Spain, the age-adjusted 
annual incidence is 125.8 cases/100,000 inhabitants and the 
mortality rate is 22.7 cases/100,000 inhabitants [1]; 32,825 
new cases were diagnosed in 2018 [2, 3].
Between 5 and 6% of breast cancer patients have meta-
static disease at the time of diagnosis, and approximately 
30% of patients diagnosed in the early stages will experience 
a relapse with the appearance of distant metastases [4]. Most 
patients diagnosed with MBC are postmenopausal women 
between 50 and 79 years of age (64–79%) [4]. Overall sur-
vival (OS) varies according to each biological subtype, and 
in the HR-positive, HER2-negative subgroup, median OS is 
42 months. At present, MBC is still incurable and the main 
treatment goal is to improve OS and quality of life [5].
Treatment response in MBC depends mainly on the bio-
logical subtype. In the HR-positive, HER2-negative subtype, 
several factors play a significant role, including status at 
diagnosis (“de novo” or relapse after treatment of local dis-
ease), previous treatment for local disease, time to relapse, 
response to previous treatments for disseminated disease, 
time to next progression, progression-free survival (PFS), 
and hormone sensitivity criteria in patients with tumors that 
express hormone receptors. The first-line treatment recom-
mended for patients with HR-positive, HER2-negative MBC 
is HT combined with cyclin-dependent kinase 4/6 (CDK4/6) 
inhibitors. The best HT option is determined by different 
factors, such as menopausal status, previous HT, and comor-
bidities. Clinical benefit from HT predicts patient survival 
and the possible benefit of subsequent HT [6]. It is estimated 
that approximately one-third of HR-positive patients present 
primary resistance to HT, the vast majority of whom develop 
secondary resistance. However, these same patients may 
respond to other types of HT. Therefore, the second-, third-, 
and fourth-line HT is administered sequentially, as resistance 
develops and the disease progresses [6, 7]. Despite the fact 
that new parameters defining hormone sensitivity have been 
described [7], hormone sensitivity and resistance criteria 
based on clinical criteria and agreed by expert consensus 
have now been adopted, even in the absence of definitive 
biological data other than the expression or non-expression 
of HR-positive, HER2-negative receptors [8]. A full defini-
tion of these criteria would help optimize health-care pro-
cesses and improve decision-making in the future.
Consensus documents are valuable tools that assist in the 
decision-making process for establishing clinical strategies 
and optimize the delivery of health services [9]. The prepa-
ration of this consensus document has been supported by 
the GEICAM Breast Cancer Research Group with the aim 
of developing recommendations on criteria for hormone sen-
sitivity and resistance in HER2-negative luminal MBC and 
facilitating clinical decision-making.
Materials and methods
This consensus document was generated using a modifica-
tion of the RAND/UCLA methodology [10]. The project 
phases were as follows. (1) Definition of the project and 
identification of issues of interest: objectives, methodol-
ogy, and clinical questions to be answered in the consen-
sus document were established. In addition, the working 
group was formed by a coordinator and a consensus group 
composed of seven oncologists, all experts in breast cancer 
who constituted the GEICAM working group on luminal 
disease between 2015 and 2018. (2) Non-exhaustive system-
atic review of the literature: we carried out a review of the 
scientific evidence from studies published between January 
2000 and April 2016, in the following databases: PubMed, 
Guía Salud, Cochrane, Trip database, and Uptodate. The 
clinical questions were reformulated into questions using 
the PICO format (population/patients, intervention, com-
parators, outcomes) [11]. This search was complemented 
with a manual search of references by the consensus group 
aimed at completing the evidence with articles that could 
be helpful for answering the questions raised. (3) Analy-
sis and synthesis of the scientific evidence: the members 
of the consensus group were responsible for systematically 
reviewing the available scientific evidence. After a critical 
reading of the full text of the selected studies, they prepared 
a summary using a standardized format, including tables 
and text to describe the methodology, the results, and the 
quality of each study. The reasons for exclusion of articles 
not included in the selection were listed. Scientific evidence 
and classification of the recommendations were evaluated 
according to the Oxford Center for Evidence-Based Medi-
cine (CEBM) system [12]. (4) Preparation of recommenda-
tions: the consensus group drew up answers to the clinical 
questions from the scientific evidence and expert clinical 
judgment. All responses included the appropriate reason-
ing and proposed conclusion(s) and recommendation(s). 
(5) External evaluation: the recommendations/conclusions 
drawn up by the consensus group underwent a process of 
external validation using a two-round Delphi technique, with 
a panel of 64 medical oncologists specializing in breast can-
cer representing the validation group. In each round, the 
members of the validation group expressed their degree of 
agreement or disagreement with the recommendations/con-
clusions using an online questionnaire with a Likert scale of 
1–4 (1 = strongly disagree; 4 = strongly agree). The recom-
mendations with a level of agreement ≥ 80% [sum of scores 
of 3 (agree) and 4 (strongly agree)] were accepted. In total, 
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all 32 of the 32 recommendations/conclusions presented in 
the first round were accepted (approval rate of 100%).
Results
1. Definition of metastatic disease or locoregional 
recurrence not susceptible to local curative 
treatment
The luminal subtype is characterized by overexpression of 
estrogen receptors (ER) and/or progesterone receptors (PR). 
HR status is determined using immunohistochemical tech-
niques on tumor biopsies. The tumor is considered HR posi-
tive if HR expression is detected in at least 1% of the nuclei 
of the invasive tumor cells. Staining in ≥ 10% of the nuclei 
indicates unambiguous positivity for the indication of HT; 
if staining is observed in 1–10% of the nuclei, the pros and 
cons of HT must be weighed up. Tumors without ER expres-
sion but with positive PR expression should be considered 
RH-positive tumors that may benefit from HT [13, 14].
Is it necessary to determine the intrinsic luminal subtype 
using gene expression platforms for therapeutic 
decision‑making in luminal MBC?
The clinical heterogeneity of breast cancer patients with 
positive HR is caused by the different gene expression pro-
files that define luminal subtypes A and B [15]. With regard 
to the classification of the tumor using gene platforms, such 
as PAM50, several studies have been performed to validate 
the results obtained with several variables of clinical inter-
est. These studies have shown that it is possible to identify 
all intrinsic genomic subtypes in patients with HR-positive, 
HER2-negative tumors [16, 17]. This genomic informa-
tion should have greater prognostic value than conventional 
clinical and pathological data [17, 18], and genomic pro-
files are more effective than immunohistochemical tech-
niques for identifying patients with luminal MBC that 
will respond to HT [PFS in patients with luminal subtype: 
11.0–16.9 months; PFS in patients with non-luminal sub-
type: 4.1–4.7 months] [17]. The latest recommendations of 
the American Society of Clinical Oncology (ASCO) on HT 
in luminal MBC specify that intrinsic genomic subtypes 
have been associated with prognosis, but their usefulness 
for selecting the most effective treatment has not yet been 
demonstrated. Thus, the determination of intrinsic subtypes 
using genomic profiles is considered experimental and 
should be reserved for the selection of patients in the clini-
cal trial setting [19].
Can luminal A and B MBC subtypes be differentiated using 
immunohistochemical techniques?
With the aim of associating genomic data with clinical and 
pathological characteristics, several studies have been con-
ducted to establish differences in the receptor expression and 
proliferative status of tumors among the different luminal 
genomic subtypes using immunohistochemical techniques 
[20, 21]. Ki-67 was the marker selected to determine pro-
liferation, defining positivity at a cutoff point of 14–20% 
[20, 22, 23]. The luminal subtype A would be defined by 
an expression below this cutoff point. PR levels have also 
been proposed as markers that might help discriminate 
between the two subtypes, with a cutoff point set at 20%. 
Thus, tumors with more than 20% of PR-positive cells would 
be considered luminal A. Published evidence indicates 
that tumors with immunohistochemical luminal subtype 
Table 1  Definitions of menopause from clinical practice guidelines
ASCO American Society of Clinical Oncology, FSH follicle-stimulating hormone, LHRH luteinizing hormone-releasing hormone, NCCN 
National Comprehensive Cancer Network, NICE National Institute for Health and Care Excellence
a A postmenopausal status cannot be assigned to women who are receiving LHRH antagonists
b Only FSH levels will be analyzed to diagnose menopause when patients are between 40 and 45 years of age and present menopausal symptoms, 
including changes in menstrual cycle or age < 40 years, suspicion of menopause, not receiving treatment with combination hormonal contracep-
tion (estrogen and progestin) or high doses of progestin
NCCN [100] Prior bilateral oophorectomy
≥ 60 years
< 60 years, and amenorrhea ≥ 12 months in the absence of chemotherapy, tamoxifen, toremifene, 
or
Ovarian suppression, and levels of FSH and estradiol within postmenopausal ranges
In case of treatment with tamoxifen or toremifene and age < 60 years, FSH and estradiol plasma 
levels must be within postmenopausal  rangesa
ASCO [19] Lack of menstruation in the past 12 months in the absence of chemotherapy
Oophorectomy, or
Ovarian suppression with LHRH agonists
NICE [101]  > 45 years with no menstruation in the last 12 months and not taking hormonal contraception, or
> 45 years with hysterectomy and menopausal  symptomsb
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A treated with HT may have a better response rate (RR), 
PFS, and overall survival (OS) post-relapse [16, 24–26] and 
appear to be less sensitive to treatment with chemotherapy 
[27] than luminal subtype B tumors.
What are the criteria for defining menopause?
It is essential that criteria for determining menopause are 
defined in patients with luminal breast cancer because, bear-
ing in mind the mechanism of action of aromatase inhibitors 
(AIs), only patients that meet strict post-menopausal criteria 
will be candidates to receive these agents, in both early and 
metastatic disease [28]. The problem lies in the fact that the 
definition of menopause varies among the different clinical 
trials and research groups [29]. Menopause is a steep and 
permanent drop in ovarian estrogen synthesis, although this 
definition is not supported by any fixed criteria, particularly 
with regard to age or months of amenorrhea [30]. Several 
definitions of menopause are listed in Table 1.
Should metastatic disease be biopsied at the time of its 
appearance and should the result guide the therapeutic 
decision?
Traditionally, the levels of various biological markers in the 
primary tumor have guided systemic treatment in metastatic 
disease, but sometimes markers in metastatic disease can 
differ with respect to the primary tumor findings. A lesion 
suspected of being metastatic breast cancer might be benign 
or it might be a second malignant tumor, thus altering prog-
nosis and treatment. Various prospective studies show that 
in 4–10% of cases, lesions suspected of being metastatic 
correspond in reality to healthy tissue, benign lesions, or 
a second malignant tumor, underlining the importance of 
biopsy for confirming the existence of breast cancer metas-
tasis, particularly at the time of initial relapse. An analysis 
of the ConvertHER study using PAM50 confirmed changes 
in the molecular subtype between the primary tumor and 
the metastasis [31, 32]. A meta-analysis [33] of data from 
individual patients from two of these studies (DESTINY 
and BRITS) showed rates of conversion between the pri-
mary tumor and the metastasis of 6%, 13%, and 31% for 
HER2, ER, and PR, respectively. The treatment plan was 
Table 2  Recommendations and conclusions on the definition of metastatic or recurrent locoregional luminal disease not susceptible to curative 
local treatment
ER estrogen receptor, ESR1 estrogen receptor 1, HER2 human epidermal growth factor receptor 2, HR hormone receptor, LA level of agreement, 
LE level of evidence, MBC metastatic breast cancer, NSAI non-steroidal aromatase inhibitors, PR progesterone receptor, RD recommendation 
degree according to Oxford
LA (%) LE/RD
HR-positive tumors are those with ≥ 1% expression of ER and/or PR in the nuclei of breast cancer tumor cells [13, 14] 90 1
Determination of intrinsic luminal subtypes using gene expression should not be the only factor considered in decision-mak-
ing in luminal MBC. Decisions on the treatment of luminal MBC (HR-positive, HER2-negative) have to be made taking into 
account biomarker results (ER, PR, HER2) from immunohistochemistry and ISH (expert opinion)
92 5/D
Menopause is defined based on the following criteria:
 Age ≥ 60 years or
 Bilateral oophorectomy or
 Age < 60 years and ≥ 12 months of amenorrhea in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppres-
sion, with levels of FSH and estradiol within postmenopausal ranges
In case of treatment with tamoxifen or toremifene and age < 60 years, FSH and estradiol plasma levels must be within post-
menopausal ranges* [28]
97 5/D
Premenopausal patients who have received chemotherapy may present anovulation/amenorrhea, without implying a loss of 
ovarian function. Therefore, FSH and estradiol levels persistently within menopausal ranges with close monitoring for a 
period of at least 2 years must be demonstrated to assign a post-menopausal status (expert opinion)
95 5/D
A biopsy (obtaining a tissue sample) of metastatic disease, if easily accessible, must be performed to confirm the diagnosis, 
especially at the beginning of metastatic disease [34–36]
99 1/B
Whenever clinically possible and technically appropriate, the study of biomarkers (ER, PR, and HER2) in metastatic disease 
is recommended (at least at the beginning of metastatic disease), as these markers can change in disease progression with 
respect to the primary tumor, so the most appropriate systemic treatment can be selected (although insufficient evidence is 
available to suggest that re-evaluation of biomarkers improves prognosis). This procedure should always be carried out if the 
biomarker status of the primary tumor is unknown and there is no access to it [34–36]
99 1/B
When discrepancies are found between ER, PR or HER2 biomarkers in the primary tumor and the metastases, the ER, PR and 
HER2 status of the metastasis should be used to guide systemic treatment, provided that it is compatible with the setting/
clinical judgment. In this case, serial biopsies from various locations are recommended for a better assessment of biomarker 
progress [35, 37]
88 5/D
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modified in 8–14% of cases after biopsy. These results are 
similar to those obtained in the previous study. Most clinical 
guidelines recommend a biopsy of metastatic lesions (one 
or more) at the time of presentation of metastatic disease, 
to confirm the nature of the metastases and to re-evaluate 
HR and HER2 status [19, 34–36]. Caution should be exer-
cised with the results obtained from tissue biopsies in which 
technical difficulties are a likelihood, such as bone biopsy 
[8, 19, 34].
Table 2 shows the recommendations and conclusions of 
the expert group with regard to this topic.
2. Definition of hormone sensitivity and hormone 
resistance in metastatic luminal disease
What variables can be used to set the definition of hormone 
sensitivity and hormone resistance in luminal MBC?
It is of the utmost importance that variables determining 
hormone resistance are identified, both for making decisions 
in clinical practice and for interpreting clinical trials [8, 19, 
37–39]. In this setting, changes in HR expression in meta-
static cells must be evaluated, although there is no evidence 
that these changes are predictive of response to any type of 
therapy [8, 19, 37, 40, 41]. Changes in HER2 expression in 
metastasis with respect to the primary tumor must also be 
taken into account. Several randomized clinical trials have 
demonstrated that the combination of HT and anti-HER2 
agents can overcome this resistance, at least in part [42, 43]. 
Vascular endothelial growth factor (VEGF) has also been 
linked to HT resistance in retrospective studies, although 
this observation was not validated in prospective studies 
conducted with bevacizumab, which produced controver-
sial results and failed to prevent the emergence of resistance 
[44, 45]. Other markers, such as Ki-67, p53, BCL-2, PI3K, 
CCDN1, p16, or multigene platforms, have not been useful 
in therapeutic decision-making [19, 46, 47]. For this rea-
son, these markers must only be considered in the context 
of clinical trials [19, 46, 47]. Other markers of resistance are 
estrogen receptor ESR1 gene mutations, which are present 
in 30% of metastases in patients who have received HT, but 
normally absent in the primary tumor [48]. Although these 
mutations can plausibly be identified, their ability to pre-
dict a good response to HT must be validated in prospective 
studies [48].
Two different scenarios must be considered when estab-
lishing the possible definition of primary or secondary 
hormone resistance. One would be time-dependent, defin-
ing relapse after adjuvant treatment, and the other would 
consider time to progression during the treatment of meta-
static disease. If relapse occurs within 2 years after begin-
ning adjuvant HT, or during the first 6 months of first-line 
HT, experts consider that resistance or insensitivity to 
HT is primary or intrinsic. In turn, when the diagnosis of 
relapse occurs more than 2 years after starting adjuvant 
HT, but within 1 year of completing adjuvant therapy, or 
if progression occurs later than 6 months after starting HT 
for metastatic disease, experts consider that resistance is 
acquired or secondary [19]. Regardless of the time periods, 
if relapse occurs during adjuvant HT, the disease is resist-
ant to that specific hormonal strategy [49]. The same occurs 
if metastatic cancer progresses within a period of less than 
1 month after discontinuation of such treatment [19, 38, 39, 
50]. Table 3 shows some of the definitions used in clinical 
practice guidelines.
Is there evidence for suggesting that a combination 
of several hormonal drugs can reverse hormone resistance 
and increase effectiveness compared to single‑agent 
hormone therapy?
Two phase III clinical trials exploring this issue in post-
menopausal women in first-line treatment for MBC, using a 
combination of anastrozole and fulvestrant, produced diverg-
ing results [1 positive: SWOG 0226 [51] (HR (hazard ratio): 
0.81; 95% confidence interval: 0.65–1.00), and 1 negative: 
Table 3  Main definitions of primary and secondary hormone resistance
Reference Primary hormone resistance Secondary hormone resistance Level of 
evidence
European Consensus guidelines [34] Relapse occurred during the first 2 years of 
adjuvant HT, or
Progressive disease in the first 6 months of HT 
in MBC
Relapse occurred after the first 2 years of 
adjuvant HT or in the first year after comple-
tion of adjuvant HT
Progressive disease occurring after the first 
6 months of HT in MBC
5
GINECO study [57] Relapse during adjuvant HT or in the first 
6 months after completion of adjuvant HT
Progressive disease in the first 6 months of HT 
in MBC
Relapse occurring later than 6 months after 
completion of adjuvant HT, or
Progression after 6 months of starting HT in 
MBC
2
Review articles: [102, 103] Progressive disease without initial response to 
treatment
Progressive disease after initial response to 
treatment
5
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FACT [52] (HR: 1.0; 95% CI: 0.76–1.32)], although when 
a subgroup analysis of the SWOG cohort was conducted, 
there was a significant benefit in OS in patients who had 
never received adjuvant HT (HR: 0.74; 95% CI: 0.56–0.98) 
[51]. The combined meta-analysis of both studies found a 
marginal but non-significant benefit in PFS (HR: 0.88; 95% 
CI: 0.72–1.09) and OS (HR: 0.88; 95% CI: 0.72–1.08) [53].
Another study in postmenopausal women who had pro-
gressed with a non-steroidal aromatase inhibitor (NSAI) 
did not find any kind of advantage with the combination of 
anastrozole and fulvestrant in comparison with single-agent 
fulvestrant or exemestane [54]. In premenopausal women, 
the combination of ovarian suppression with tamoxifen in 
first line was superior to ovarian suppression in terms of OS 
(HR: 0.78; 95% CI: 0.63–0.96) and PFS (HR: 0.70; 95% CI: 
0.58–0.85) [55].
The international guidelines of the European School 
of Oncology–European Society of Medical Oncology 
(ESO–ESMO) and ASCO recommend the use of sequential 
single-agent HT in postmenopausal patients [19, 34] and 
only recommend the combination of anastrozole and fulves-
trant in patients who have not received any adjuvant treat-
ment [19]. In the case of premenopausal patients, a combina-
tion of ovarian suppression with tamoxifen is recommended 
in first line, and in subsequent lines, ovarian suppression 
should be maintained, and patients should be treated in the 
same way as postmenopausal women [19, 34].
Is there evidence for suggesting that HT combined 
with chemotherapy can reverse hormone resistance 
and increase effectiveness compared to single‑agent 
hormone therapy?
The analysis of some studies suggest that the sequential use 
of each type of treatment is equivalent to their combination, 
and data in the adjuvant setting even suggest that combined 
use may be less effective than sequential use [56]. However, 
the luminal subtype has not been specifically investigated in 
any recent study. Therefore, international clinical guidelines 
do not recommend the combination of HT with chemother-
apy [19, 34].
Is there evidence for supporting the use of HT combined 
with targeted therapies instead of single‑agent hormone 
therapy to reverse hormone resistance and increase 
effectiveness in HR‑positive, HER2‑negative MBC?
One of the possible mechanisms of resistance to HT is acti-
vation of the cellular pathways that might interfere with 
inhibition of the hormone-dependent pathway. One of these 
pathways is PI3K. Several studies have been published on 
the mTOR inhibitors, including everolimus and tamoxifen 
[time to progression (TTP) HR: 0.54; 95% CI: 0.36–0.81] 
[57] and everolimus and exemestane (OS: HR: 0.89; 95% 
CI: 0.73–1.10) [58]. As such, everolimus has been approved 
for use in combination with exemestane after failure of an 
NSAI, as reflected in international clinical guidelines [19, 
34]. Tensirolimus in combination with fulvestrant (PFS: HR: 
0.61; 95% CI: 0.40–0.92) [59] showed a significant increase 
in PFS. A phase III study evaluated the effect of a combina-
tion of tensirolimus and letrozole in first-line therapy, and 
did not find a benefit in PFS for the combination (HR: 0.90; 
95% CI: 0.76–1.07) [60]. The data on PI3K inhibitors are 
still very preliminary. The SOLAR-1 study has shown an 
increase in PFS in second-line treatment in patients with 
tumors with a PI3K mutation (HR: 0.65; 95% CI: 0.50–0.85) 
[61].
Two studies in first line with bevacizumab in combination 
with letrozole produced diverging results, one being negative 
for PFS (HR: 0.83; 95% CI: 0.65–1.06) [45] and the other 
positive (HR: 0.75; 95% CI: 0.59–0.96) [44]. For this reason, 
its use has not been recommended in clinical guidelines [62].
The use of anti-EGFR inhibitors (HER1), such as gefi-
tinib, or anti-HER1/2, such as lapatinib, in patients with HR-
positive, HER2-negative MBC has not proved effective and 
is not recommended [63–65].
Three cyclin-D-dependent kinase (CDK)4/6 inhibitors, 
ribociclib, abemaciclib, and palbociclib, have been studied. 
In the case of palbociclib, data from two studies (a rand-
omized phase II study [66] and a phase III study [67] in 
which palbociclib was combined with letrozole in first-line 
therapy in postmenopausal women) have been published. 
Both studies showed an increase in PFS with HT alone. 
There are also data on second-line treatment in combination 
with fulvestrant, which show an increase in PFS compared 
to HT alone in both postmenopausal and premenopausal 
women, associated in the latter with ovarian suppression 
with luteinizing hormone-releasing hormone (LHRH) ana-
logues (HR: 0.49; 95% CI: 0.32–0.75) and HR: 0.50; 95% 
CI: 0.33–0.76], respectively) [38, 68]. In the case of ribo-
ciclib, data have been published on a phase III study in first 
line in postmenopausal women, in which it was combined 
with letrozole, showing an increase in PFS compared to HT 
alone (HR: 0.56; 95% CI: 0.43–0.72) [69]. In the case of 
abemaciclib, data have been published from two studies: a 
phase III study, in which abemaciclib was combined with an 
NSAI, anastrozole, or letrozole, in first line [70] and another 
phase III study in which it was combined with fulvestrant in 
second line [71]; in both cases an increase in PFS was found 
compared with HT alone (HR: 0.54; 95% CI: 0.41–0.72 and 
HR: 0.55; 95% CI: 0.45–0.68), respectively). Data have also 
been presented from a phase II study of abemaciclib mono-
therapy in patients polytreated with HT and chemotherapy, 
showing a response rate of up to 17% [72].
Table 4 shows the recommendations of the expert group 
with regard to hormone resistance and hormone sensitivity.
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3. Therapeutic decision‑making
Can the menopausal status influence the selection 
of first‑line treatment? Should ovarian function be 
suppressed in first‑line treatment?
The selection of the optimal HT in patients with HR-posi-
tive, HER2-negative MBC should be guided by menopau-
sal status, previously administered HT, and the patient’s 
comorbidities [19, 73]. Very few clinical trials have included 
premenopausal women in their designs, especially in first-
line strategies [74]. The choice of treatment in first line 
depends on the adjuvant treatment, which may be chemical 
or surgical castration [19]. Studies comparing the effective-
ness of tamoxifen and oophorectomy in this type of patients 
found no significant differences for the various clinical 
parameters under study [75, 76]. LHRH analogs with or 
without tamoxifen had similar results to oophorectomy 
[77]. The combination of LHRH analogs and tamoxifen 
Table 4  Recommendations and conclusions on the definition of hormone sensitivity-hormone resistance in metastatic luminal disease
ER estrogen receptor, ESR1 estrogen receptor 1, HER2 human epidermal growth factor receptor 2, HT Hormone therapy, LA level of agreement, 
LE level of evidence, MBC metastatic breast cancer, mTOR mammalian target of rapamycin, NSAI non-steroidal aromatase inhibitors, PR pro-
gesterone receptor, RD recommendation degree according to Oxford
*Currently, ribociclib and abemaciclib are also indicated in premenopausal patients. Palbociclib is the only cyclin-dependent kinase inhibitor 
mentioned because ribociclib and abemaciclib had not still the indication in this subgroup of patients when the external validation using a two-
round Delphi technique was done
LA (%) LE/RD
Negativization (< 1%) of hormone receptors in metastatic cells should be considered as hormone resistance, so ER, PR and 
HER2 of a new metastasis should be determined whenever possible before making therapeutic decisions (expert opinion)
95 5
A high level of hormone receptors makes hormone sensitivity more likely. However, there is no accurate cutoff point or score 
that indicates hormone resistance, so any tumor with ER ≥ 1% can theoretically be hormone sensitive (expert opinion)
93 5
The only unequivocal criterion of hormone resistance is progression during a hormonal intervention. Progressive disease 
during the first 6 months of HT for MB or during the first 2 years of (neo-)adjuvant HT is evidence of resistance to hormone 
therapy, so the line of treatment must be changed [19, 50]
97 2
Intracellular signaling markers and ER mutations (ESR1) should not be taken into account when deciding to use HT outside 
the setting of a clinical trial [19, 37]
93 2/B
In the context of disease relapse after adjuvant treatment, progression occurring during the first 2 years of adjuvant treatment 
can be considered as primary or refractory hormone resistance [34]
97 5
In the context of MBC, progression in the first 6 months of HT can be considered primary hormone resistance [34] 97 5
Insufficient evidence was found to answer this question. However, in the context of relapse during or after adjuvant treatment, 
relapse occurring later than 2 years after starting treatment and within 1 year after completion could be considered second-
ary hormone resistance [34]
95 5
In the context of metastatic disease, progressive disease after an initial benefit with HT within the first 6 months of treatment 
is considered secondary hormone resistance [34]
92 5
In postmenopausal women, there is insufficient evidence to recommend the combination of two hormone agents simultane-
ously. Thus, HT in sequential monotherapy is recommended [19, 34]
97 1/A
In the case of premenopausal women, a combination of ovarian suppression with tamoxifen or AI in first line is recommended 
[19, 34]
95 1/B
In premenopausal women, ovarian suppression should be maintained and sequential HT should be added as in postmenopau-
sal women in second line and in subsequent lines [19, 34]
93 3/C
In patients with HR-positive, HER2-negative advanced breast cancer, the use of a combination of TH and chemotherapy is 
recommended. Sequential administration is recommended, with HT being the preferred option in first line and in succes-
sive lines until the emergence of resistance. The use of chemotherapy as a first option is preferable in a critical situation of 
visceral disease requiring a quick response [19, 34, 56]
99 2/C
In postmenopausal patients, cyclin-dependent kinase inhibitors ribociclib and palbociclib in combination with an NSAI are 
recommended as a treatment option in first-line HT. Palbociclib is also recommended in second line in combination with 
fulvestrant after failure on first-line therapy (palbociclib is also indicated in premenopausal* patients in combination with an 
NSAI or fulvestrant with an LHRH analog) [38, 66–69, 74]
97 1/A
In postmenopausal patients, the combination of exemestane with everolimus is recommended in the absence of symptomatic 
visceral disease after failure of an NSAI. The use of mTOR inhibitors is not recommended in patients who have not previ-
ously received an NSAI or in cases of MBC de novo or those who have relapsed after more than 1 year after the end of 
adjuvant treatment [19, 34]
97 2/B
The use of antiangiogenic drugs in combination with HT is not recommended [19, 34] 89 2/B
The use of HER1/2 inhibitors in combination with HT in HR-positive, HER2-negative MBC is not recommended [63–65] 95 2/B
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was superior to tamoxifen in terms of response rate, TTP, 
and OS [78].
What are the criteria for tumor “aggressiveness” in luminal 
MBC that would indicate the need for chemotherapy?
Several studies have demonstrated similar rates of disease 
control and OS (HR: 0.94; 95% CI: 0.79–1.12) between HT 
and chemotherapy [79]. Although chemotherapy can achieve 
a greater number of responses, the toxicity profile favors 
HT. In addition, the presence of visceral disease (non-life-
threatening) has not been shown to reduce the benefit of 
HT. Numerous reviews highlight HT as the treatment of 
choice in first line and in subsequent lines of treatment in 
HR-positive, HER2-negative MBC, reserving chemother-
apy for cases with imminent failure of a vital organ [56, 
80], symptomatic visceral disease, and/or rapid growth [56, 
80, 81], or HT resistance, including previous combinations 
of HT and targeted therapies, such as mTOR inhibitors or 
cyclin-dependent kinase inhibitors, the aim of which is to 
delay or reverse the development of this endocrine resist-
ance [81, 82]. These results have prompted clinical practice 
guidelines such as ASCO to consider chemotherapy as an 
appropriate initial treatment in patients with imminent life-
threatening disease, in whom the time to response can be 
critical. It may also be considered as a first option in patients 
with low HR levels in whom HT may be less effective [19]. 
The ESO–ESMO clinical guidelines for MBC also assert 
the recommendation to reserve chemotherapy for cases with 
rapidly progressive disease or confirmed endocrine resist-
ance. In other situations, HT is still the first option, even in 
the presence of visceral disease [34]. The National Breast 
and Ovarian Cancer Center (NBOCC) guidelines also rec-
ommend using chemotherapy only in cases of rapidly pro-
gressing visceral disease [83]. The Canadian guidelines offer 
alternatives in postmenopausal women with HR-positive, 
HER2-negative MBC who relapse or progress after treat-
ment with an NSAI, proposing other hormone treatments or 
a combination of everolimus and exemestane in patients with 
endocrine resistance and slow progression. Chemotherapy 
Table 5  Recommendations on therapeutic decision-making
AI aromatase inhibitor, CTC circulating tumor cell, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HT hormone ther-
apy, LE level of evidence, LA level of agreement, MBC metastatic breast cancer, mTOR mammalian target of rapamycin, PET positron emission 
tomography, RD recommendation degree according to Oxford
LA (%) LE/RD
Menopausal status should not be taken into account when deciding whether to use chemotherapy or HT in patients with ER-
positive, HER2-negative MBC [79]
89 5/D
Menopausal status should be taken into account when selecting HT in patients with ER-positive, HER2-negative disease [19, 
73]
90 5/D
In premenopausal patients with ER-positive MBC, ovarian ablation in combination with another HT should be recommended. 
In patients who have never received HT or who relapse more than 12 months after completing adjuvant HT, combined ovar-
ian ablation or suppression should be recommended [75, 76]
96 2/B
In premenopausal patients with ER-positive MBC who have never received HT or who relapse after 12 months since complet-
ing adjuvant HT, ovarian suppression or ablation should be recommended in combination with tamoxifen or AI ± cyclin 
inhibitors as first-line treatment, provided that there is no visceral crisis [55]
97 1/A
In premenopausal patients with ER-positive MBC who relapse during adjuvant HT or in the 12 months after completion of 
adjuvant HT, ovarian ablation could be combined with an AI or fulvestrant, as in postmenopausal patients, although the 
evidence is still inadequate [78]
93 3/C
Suggested criteria for tumor “aggressiveness” in luminal MBC that would indicate the need for treatment with chemotherapy 
are as follows:
 Rapidly progressing or very symptomatic disease
 Disease compromising a vital organ or imminent risk to life
Disease with demonstrated endocrine resistance, even after previous treatment with targeted therapies (mTOR or cyclin 
inhibitors, for example) casting doubt on the possible response to HT (expert opinion)
99 5/D
Serum markers may not be used as the sole criterion for defining progression (resistance) or for starting, stopping or changing 
HT. However, progressive and sustained elevation (two determinations more than 1 month apart) of CA 15. 3 and/or CEA 
could be useful in unmeasurable disease to raise suspicion of progression (resistance) and to request imaging tests to confirm 
progression (evaluation of PET/CT) (expert opinion)
97 5/D
In the event of a sustained elevation of serum marker CA15.3 and/or CEA during HT, imaging studies should be requested to 
document any progression/hormone resistance. At this stage, PET/CT is more sensitive than conventional methods, espe-
cially in the evaluation of pathological axillary, supraclavicular, internal mammary chain, and mediastinal lymphadenopa-
thies [56, 85]
90 3/C
CTC and circulating c-erbB-2 extracellular domain should not be used as the sole criterion to start, stop or change HT [19, 34, 
37, 88]
99 2/C
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is limited to patients with resistance to HT and sympto-
matic visceral disease [78]. The Spanish Society of Medical 
Oncology (SEOM) guidelines for MBC published in 2018 
specify that chemotherapy should be standard treatment in 
patients who are refractory to HT [84].
Are serum biomarkers useful?
A series of serum biomarkers has emerged in recent years, 
including CA15.3, CEA, CA 27.29, circulating tumor cells 
(CTC), and circulating erbB-2 extracellular domain that 
could help determine resistance to hormonal interventions. 
Some prospective studies have shown that the combination 
of several of these serum markers, such as CEA and CA 
15.3 [85, 86], or CTC and CA 27.29 [87], is more sensi-
tive than using them singly in the diagnosis of metastatic 
relapse. However, randomized phase III studies have not 
shown any survival benefit from the serial determination of 
serum markers [88], nor is there any evidence that initiating 
or changing treatment on the basis of serum markers or CTC 
confers an improvement in health status, survival, or quality 
of life [19, 34, 37, 88]. Three expert consensus articles also 
agree that no well-designed studies are available to evaluate 
the clinical utility of the markers [19, 34, 37]. Nevertheless, 
this is the only method for monitoring unevaluable meta-
static disease [19, 34, 37, 85, 86].
Table 5 shows the recommendations of the expert group 
with regard to therapeutic decision-making.
Discussion
Consensus documents prepared by independent committees 
are a valuable tool for decision-making in areas in which evi-
dence is limited or could not be combined to establish clini-
cal strategies or improve efficiency in the delivery of health 
services [9]. The preparation of this consensus document has 
been sponsored by the GEICAM Breast Cancer Research 
Group, and is the product of the dedicated involvement of 
the members of the GEICAM Luminal Disease Working 
Group. This consensus was developed following a robust, 
recognized, and rigorous methodology, but a number of 
limitations inherent to documents of this type must be taken 
into account. In the first place, the review of the literature, 
while systematic, was not exhaustive, and only the most cur-
rent publications were included. Furthermore, after the ini-
tial literature review, the development of recommendations 
and consensus took longer than expected, which is why, 
after they were completed, we had to perform an additional 
search to update specific themes to take into account recent 
advances in the treatment of luminal MBC. The following 
is a summary of the main results of this additional review.
With respect to the combination of everolimus with HT, 
results have been published showing that the combination of 
everolimus with fulvestrant in second-line therapy increases 
PFS from 5.1 to 10.3 months (HR: 0.61; 95% CI: 0.40–0.92) 
[89], results that are in line with data from the phase III 
study of everolimus plus exemestane [90]. With regard 
to PI3K inhibitors (selective or pan-PI3K inhibitors), the 
results of phase III trials of buparlisib [91, 92] and taselisib 
[93], both in combination with fulvestrant, have recently 
been published. Toward the end of 2018, data were pre-
sented on alpelisib (a selective inhibitor of the PI3K alpha 
subunit) in combination with fulvestrant showing increased 
PFS in patients with PIK3CA mutations [61]. While the first 
two showed positive but clinically non-significant results, 
the selective inhibitor alpelisib did yield data on statistically 
significant efficacy and clinically manageable safety in the 
second-line treatment of patients with ER+/HER2−/PI3CA-
mutated breast cancer. With regard to CDK4/6 inhibitors, 
the results of phase III studies of ribociclib combined with 
tamoxifen and LHRH analogs in first line in premenopausal 
patients [94] and with fulvestrant in first and second line in 
postmenopausal patients [95] have been published, showing 
the same benefit in PFS. These results give greater coher-
ence to the use of CDK4/6 inhibitors in combination with 
HT in the first- or second-line treatment of luminal MBC. 
Finally, data were presented at ASCO 2019 on the impact 
on OS of ribociclib combined with HT in premenopausal 
patients who, for the first time, showed an increase in OS 
with the combination of HT and CDK4/6 inhibitors [96], and 
later in ESMO 2019 the benefit in OS has been presented 
in other two trials, one for the combination of ribociclib 
with fulvestrant in first and second line in postmenopausal 
women (MONALEESA3) [97] and the other for abemaciclib 
in combination with fulvestrant in second line [98].
The classification of luminal subtypes A and B is based 
on gene expression and their correlation with immunohis-
tochemistry is not complete. There is no evidence to sug-
gest that the subclassification of luminal type A or B using 
immunohistochemical techniques, in the absence of other 
factors, should influence therapeutic decision-making. A 
meta-analysis which included the analysis of 39 studies 
found that the conversion rates of receptors in metastasis 
of advanced breast cancer patients are high. It is recom-
mended that biopsies are performed to confirm the status 
of these receptors in metastasis, although more prospective 
studies would need to be conducted to determine whether 
this conversion has some type of impact on the effectiveness 
of treatment in terms of survival [99].
Medical oncology is a field in which new data are con-
stantly emerging. These updates oblige us to respond to 
questions that arise from the new evidence, including, for 
example, the diagnostic role of new technologies, such 
as genomic platforms and liquid biopsy. Other areas of 
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therapeutic interest might be determining suitable patient 
profiles for biologics and combination therapies (HT with 
biologics), as well as their sequence. Other issues might 
address those profiles in which chemotherapy will be more 
effective or the duration of administration of antiresorptive 
therapies. With regard to follow-up, questions are being 
raised on the aggressiveness of tumors that have developed 
resistance to cyclin-dependent kinase inhibitors, the role 
of fulvestrant in first line to avoid the appearance of ESR1 
mutations, and quality of life issues. Other questions to be 
resolved surround the primary objectives of clinical trials 
and the role of combined therapies in advanced luminal can-
cer. Answers to these and other questions should become 
available from future studies to be able to continue offering 
improvements in the treatment of patients with advanced 
luminal breast cancer.
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